Terms: = Ovarian cancer AND BCL10, CIPER, 8915, ENSG00000142867, c-E10, CARMEN, mE10, CLAP
6 results:
1. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
[TBL] [Abstract] [Full Text] [Related]
2. The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.
Dueckelmann AM; Fink D; Harter P; Heinzelmann V; Marth C; Mueller M; Reinthaller A; Tamussino K; Wimberger P; Sehouli J
Arch Gynecol Obstet; 2018 Apr; 297(4):837-846. PubMed ID: 29356953
[TBL] [Abstract] [Full Text] [Related]
3. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.
Huh JH; Kim TH; Kim K; Song JA; Jung YJ; Jeong JY; Lee MJ; Kim YK; Lee DH; An HJ
Br J Cancer; 2013 Jul; 109(2):452-61. PubMed ID: 23807165
[TBL] [Abstract] [Full Text] [Related]
4. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.
Solar P; Feldman L; Jeong JY; Busingye JR; Sytkowski AJ
Int J Cancer; 2008 Jan; 122(2):281-8. PubMed ID: 17893875
[TBL] [Abstract] [Full Text] [Related]
5. Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Mahanivong C; Chen HM; Yee SW; Pan ZK; Dong Z; Huang S
Oncogene; 2008 Feb; 27(9):1273-80. PubMed ID: 17724468
[TBL] [Abstract] [Full Text] [Related]
6. bcl10 is not a target for frequent mutation in human carcinomas.
Lambers AR; Gumbs C; Ali S; Marks JR; Iglehart JD; Berchuck A; Futreal PA
Br J Cancer; 1999 Jul; 80(10):1575-6. PubMed ID: 10408401
[TBL] [Abstract] [Full Text] [Related]
